Abu Dhabi:ADCAN Pharma has entered into a Memorandum of Understanding (MoU) with M42, a global leader in health powered by artificial intelligence, technology, and genomics. This collaboration aims to boost pharmaceutical manufacturing and clinical research in the United Arab Emirates (UAE), thereby enhancing its life sciences sector and role in global pharmaceutical supply chains.
According to Wam, the MoU will see both organizations explore opportunities in contract development and manufacturing through Glenmark Pharmaceuticals. The focus will initially be on secondary packaging and export-oriented pharmaceutical supply. This phase follows a successful quality audit of ADCAN Pharma's facility by Glenmark, paving the way for the project's advancement.
The next steps involve facilitating the UAE registration of an advanced oncology product based on an antibody-drug conjugate, a targeted cancer therapy. This phase will include potential batch releases for key export markets, pending regulatory approvals.
ADCAN Pharma will further support clinical trial activities led by IROS, M42's contract research organization, integrating clinical research with pharmaceutical development and manufacturing efforts.
The collaboration aims to expand ADCAN Pharma's business in CDMO and secondary packaging, while supporting M42's clinical research goals. It aligns with Abu Dhabi's strategy to develop a connected life sciences ecosystem linking local and global markets.
The MoU was signed at the Abu Dhabi Future Health Summit 2026 by Dr. Fokion Sinis, CEO of ADCAN Pharma, and Dr. David Kavanagh, Acting COO of M42's Integrated Health Solutions, witnessed by senior representatives from both entities.
